Pharmaceuticals
Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China
NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients SHANGHAI, May 22, 2026 /PRNewswire/ -- Nuance Pharma today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application, enabl...
2026-05-22 09:50
870
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
* Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506) * Efficacy and safety of lunbotinib fumarate (A...
2026-05-22 08:00
1187
Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
CHENGDU, China, May 21, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's tropho...
2026-05-21 22:08
2649
WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization
TOKYO, May 20, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), recently hosted its third CRDMO Day in Tokyo, bringing together senior leaders and experts from Japan's biopharmaceutical industry, exchanging the ...
2026-05-20 13:44
1466
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-05-20 08:00
2844
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
* IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. * Maximum dose reached with no dose-limiting toxicities observed. * TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma. MELBOURNE, Australia ...
2026-05-19 05:00
2755
MS Pharma Announces Strategic Growth Investment from Olayan Financing Company
Strategic Partnership to Accelerate Growth in Saudi Arabia and Across the MENA Region AMMAN, Jordan and RIYADH, Saudi Arabia, May 18, 2026 /PRNewswire/ -- MS Pharma today announced that Olayan Financing Company (OFC) has made a minority equity investment in the company. This partnership brings s...
2026-05-18 20:39
2047
Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
* Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2 * Current treatments are limited by suboptimal disease control and treatment-related complications3,4 * Asedebart (Lu AG13...
2026-05-18 17:10
2334
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global precision oncology company, today announced that ...
2026-05-14 23:58
3626
CHEPLAPHARM to Accelerate Global Supply Chain Digitalization with TraceLink MINT
The German pharmaceutical company unifies its digital partner network, laying the foundation for AI-driven supply chain orchestration BOSTON, May 14, 2026 /PRNewswire/ -- TraceLink, the world's largest Agentic Business Network, today announced that the German-based but globally active CHEPLAPHAR...
2026-05-14 22:00
3384
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study - Japan Phase 3 results strengthen CARTISTEM's® global commercial prospects, with Japan biologics license application (BLA) scheduled for 2H 2026 SEOUL, South Korea and...
2026-05-14 10:30
3214
Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) appro...
2026-05-13 08:00
3243
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Bi...
2026-05-12 22:27
3135
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology leader and oncology drug-development executive, joins Halia ...
2026-05-12 20:39
3000
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug...
2026-05-12 20:30
3282
New Data Show Gaps in Antiviral Pipeline Against High-Risk Viral Threats
Longitudinal analysis reveals clear gaps in global preparedness against emerging viral threats and future pandemics. CAMBRIDGE, Mass., May 12, 2026 /PRNewswire/ -- New global analysis of antiviral compounds released today has identified a critically thin pipeline of treatments in development tha...
2026-05-12 19:00
2064
Avalere Health expands to Japan with a full-service Advisory, Medical, and Marketing offering, led by industry veteran Junji Yokokawa
Avalere Health Japan is designed with the full healthcare experience in mind, launching with an elite integrated team that brings together market access, medical, and marketing specialists, along with strategic consulting expertise. TOKYO, May 11, 2026 /PRNewswire/ -- Avalere Health, a global str...
2026-05-11 13:30
1979
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
TOKYO, May 11, 2026 /PRNewswire/ -- ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficient drug discov...
2026-05-11 08:00
2493
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
SEOUL, South Korea, May 11, 2026 /PRNewswire/ -- ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficien...
2026-05-11 08:00
2376
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for review ...
2026-05-08 19:29
4756
Week's Top Stories
Most Reposted
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 293 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
8049
